Sponsor Deadline
Posted: 4/18/2022

Biomarkers for the Lewy Body Dementias (U01 Clinical Trial Not Allowed)

The purpose of this funding opportunity announcement (FOA) is to support hypothesis-driven clinical research applications that are focused on discovering novel diagnostic, prognostic, and/or therapeutic biomarkers for the Lewy Body Dementias (LBD). Biomarker research must be conducted in patients with LBD, must follow Parkinson's Disease Biomarker Program (PDBP) protocols for clinical assessment and biospecimen collection, and must be broadly shareable through the PDBP repositories.

Deadlines:

  • Application Due Date(s): October 22, 2021

RFA-NS-22-001 Expiration Date November 23, 2021

Funding Type
Eligibility
Posted
4/18/2022
Deadline
Sponsor: